从增加高危人群定期筛查依从性谈原发性肝癌早期诊断

罗心晨; 周友乾

doi:10.3969/j.issn.1001-5256.2018.08.044

从增加高危人群定期筛查依从性谈原发性肝癌早期诊断

DOI: 10.3969/j.issn.1001-5256.2018.08.044

解放军第一六九医院暨湖南师范大学附属湘南医院感染科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1816
- HTML全文浏览量: 55
- PDF下载量: 367
- 被引次数: 0
出版历程
- 收稿日期: 2018-05-03
- 出版日期: 2018-08-20

Increasing early diagnosis of primary liver cancer by improving the compliance with regular screening in the high-risk population

Department of Infectious Diseases, 169 Hospital of PLA & Xiangnan Hospital Affiliated to Hunan Normal University

摘要

摘要: 原发性肝癌患者诊断时多已为中晚期,失去最佳治疗时机,而提高原发性肝癌的早期诊断率对于改善患者预后具有重要意义。新型血清肿瘤标志物的研究进展迅速,但临床应用仍有不太理想之处,根据原发性肝癌高危人群病史信息和常规筛查指标等多因素综合早期风险预测进行风险再分层,针对不同风险等级采取相应的筛查方式,有利于增加患者依从性,进而提高原发性肝癌的早期诊断率。就目前原发性肝癌早期诊断现状及高危人群早期筛查方法和早期发病风险预测等方面的研究进展进行阐述。
- 肝肿瘤 /
- 病人依从 /
- 早期诊断 /
- 综述
Abstract: Most patients with primary liver cancer are in the advanced stage at diagnosis and have missed the best timing of treatment, and therefore, increasing the early diagnostic rate of primary liver cancer has great significance in improving patients' prognosis. There is a rapid progress in the research on new serum tumor markers, but their clinical application is still not satisfactory. The screening method of risk re-stratification based on the medical history of individuals at a high risk of primary liver cancer and conventional screening indices and adoption of different ways of screening based on the level of risk can improve patient compliance and thus increase the early diagnostic rate of primary liver cancer. This article reviews the research advances in the current status of early diagnosis of primary liver cancer, the early screening methods in the high-risk population, and early risk prediction.
- liver neoplasms /
- patient compliance /
- early diagnosis /
- review

HTML全文

参考文献(42)

[1]CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66 (2) :115-132.

[2]TONG MJ, ROSINSKI AA, HUYNH CT, et al.Long-term survival after surveillance and reatment in patients with chronic viral hepatitis and hepatocellular carcinoma[J].Hepatol Commun, 2017, 1 (7) :595-608.

[3]National Health and Family Planning Commission of the People’s Republic of China.Diagnosis, management and treatment of hepatocellular carcinoma (V2017) [J].J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.

[4]ZHANG CY, FU Y, LI XD, et al.Advances in imaging diagnosis of liver cancer[J].J Clin Hepatol, 2017, 33 (7) :1266-1269. (in Chinese) 张春雨, 付宇, 李晓东, 等.肝癌的影像学诊断进展[J].临床肝胆病杂志, 2017, 33 (7) :1266-1269.

[5]ZHONG JH, PENG NF, YOU XM, et al.Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China:A real-world study[J].Oncotarget, 2017, 8 (11) :18296-18302.

[6]PANDYA P, KANWAL F.Adding to the evidence base:Effectiveness of hepatocellular carcinoma surveillance in clinical practice[J].Hepatol Commun, 2017, 1 (8) :723-725.

[7]JEONG WK.Surveillance of hepatocellular carcinoma:Is only ultrasound enough?[J].Clin Mol Hepatol, 2017, 23 (3) :222-223.

[8]TZARTZEVA K, OBI J, RICH NE, et al.Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis:A Meta-analysis[J].Gastroenterology, 2018, 154 (6) :1706-1718.

[9]FREY RS, BOLDANOVA T, HEIM M.Ultrasound surveillance for hepatocellular carcinoma:Real-life performance in a hepatology outpatient clinic[J].Swiss Med Wkly, 2015, 145:w14200.

[10]LU LG.Advances in early screening and diagnosis of hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (7) :1257-1261. (in Chinese) 陆伦根.原发性肝癌的早期筛查及诊断[J].临床肝胆病杂志, 2017, 33 (7) :1257-1261.

[11]WANG M, DEVARAJAN K, SINGAL AG, et al.The Doylestown algorithm:A test to improve the performance of AFP in the detection of hepatocellular carcinoma[J].Cancer Prev Res, 2016, 9 (2) :172-179.

[12]SONG PP, XIA JF, INAGAKI Y, et al.Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma[J].World J Gastroenterol, 2016, 22 (1) :262-274.

[13]WONG RJ, AHMED A, GISH RG.Elevated alpha-fetoprotein:Differential diagnosis-hepatocellular carcinoma and other disorders[J].Clin Liver Dis, 2015, 19 (2) :309-323.

[14]AHMED MOHAMMED HF, ROBERTS LR.Should AFP (or any biomarkers) be used for HCC surveillance?[J].Curr Hepatol Rep, 2017, 16 (2) :137-145.

[15]OMATA M, CHENG AL, KOKUDO N, et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma:A 2017 update[J].Hepatol Int, 2017, 11 (4) :317-370.

[16]LI B, LI B, GUO T, et al.Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels ofα-fetoprotein, α-fetoprotein-L3, des-γ-carboxy prothrombin, and Golgi protein 73[J].Oncotarget, 2017, 8 (46) :80521-80530.

[17]YANG GM, ZHAO YS, WANG CH, et al.Research advances in tumor markers for the diagnosis of hepatocellular carcinoma[J].J Clin Hepatol, 2018, 34 (1) :199-203. (in Chinese) 杨贵敏, 赵运盛, 王春华, 等.肝细胞癌肿瘤标志物的研究进展[J].临床肝胆病杂志, 2018, 34 (1) :199-203.

[18]WANG J, ZHANG SG, SUN Y, et al.The application value of GPC-3 and CK-19 in the diagnosis of hepatocellular carcinoma[J].J Clin Exp Med, 2017, 16 (14) :1398-1404. (in Chinese) 王娟, 张曙光, 孙颖, 等.免疫组化检测GPC-3与CK-19在肝细胞癌诊断中的应用价值[J].临床和实验医学杂志, 2017, 16 (14) :1398-1404.

[19]SU YH, LIN SY, SONG W, et al.DNA markers in molecular diagnostics for hepatocellular carcinoma[J].Expert Rev Mol Diagn, 2014, 14 (7) :803-817.

[20]XU RH, WEI W, KRAWCZYK M, et al.Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J].Nat Mater, 2017, 16 (11) :1155-1161.

[21]DUCHARTRE Y, KIM YM, KAHN M.The Wnt signaling pathway in cancer[J].Crit Rev Oncol Hematol, 2016, 99:141-149.

[22]BAI ZF, DONG F, CHAI X, et al.Research advances on the serological markers in early screening and diagnosis of hepatocellular carcinoma[J].Chin J Gastroenter Hepatol, 2016, 25 (5) :589-593. (in Chinese) 柏兆方, 董方, 柴煊, 等.肝癌血清学早期筛查与诊断标志物研究进展[J].胃肠病学和肝病学杂志, 2016, 25 (5) :589-593.

[23]ZHANG Z, ZHANG Y, WANG Y, et al.Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma[J].Onco Targets and therapy, 2016, 9:123-129.

[24]JIA Z, WANG L, LIU C, et al.Evaluation ofα-fetoprotein-L3and Golgi protein 73 detection in diagnosis of hepatocellular carcinoma[J].Contemp Oncol, 2014, 18 (3) :192-196.

[25]JUNNA Z, GONGDE C, JINYING X, et al.Serum AFU, 5'-NT and AFP as biomarkers for primary hepatocellular carcinoma diagnosis[J].Open Med, 2017, 12 (1) :354-358.

[26]LI C, ZHANG Z, ZHANG P, et al.Diagnostic accuracy of desgamma-carboxy prothrombin versus alpha-fetoprotein for hepatocellular carcinoma:A systematic review[J].Hepatol Res, 2014, 44:e11-e25.

[27]PARK SJ, JANG JY, JEONG SW, et al.Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma[J].Medicine (Baltimore) , 2017, 96 (11) :e5811.

[28]ZHANG XM, WEI MJ, XU ZJ, et al.Pattern of serumα-fetal protein, intereleukin-6 and Golgi protein 73 expressed in liver disease and their diagnostic value on hepatocellular carcinoma[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition, 2017, 11 (4) :339-344. (in Chinese) 张小曼, 魏梅娟, 许正锯, 等.血清甲胎蛋白、白细胞介素-6和高尔基体蛋白73在肝脏疾病中的表达特点及其对肝细胞癌的诊断价值[J/CD].中华实验和临床感染病杂志:电子版, 2017, 11 (4) :339-344.

[29]ZHU J, JIANG F, NI HB, et al.Combined analysis of serumγ-glutamyl transferase isoenzyme II, α-L-fucosidase andα-fetoprotein detected using a commercial kit in the diagnosis of hepatocellular carcinoma[J].Exp Ther Med, 2013, 5 (1) :89-94.

[30]CHEN H, CHEN S, LI S, et al.Combining des-gamma-carboxyprothrombin and alpha-fetoprotein for hepatocellular carcinoma diagnosing:An update meta-analysis and validation study[J].Oncotarget, 2017, 8 (52) :90390-90401.

[31]MITTAL S, KANWAL F, YING J, et al.Effectiveness of surveillance for hepatocellular carcinoma in clinical practice:A United States cohort[J].J Hepatol, 2016, 65 (6) :1148-1154.

[32]GOLDBERG DS, ADDEI TH, SERPER M, et al.Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis[J].Hepatology, 2017, 65 (3) :864-874.

[33]DING HG.Standardized screening and monitoring of primary liver cancer should be taken seriously[J].Beijing Med J, 2013, 35 (6) :409-411. (in Chinese) 丁惠国.重视原发性肝癌的规范化筛查与监测[J].北京医学, 2013, 35 (6) :409-411.

[34]HAN KH, AHN SH.How to predict HCC development in patients with chronic B viral liver disease[J].Intervirology, 2005, 48 (1) :23-28.

[35]YANG HI, SHERMAN M, SU J, et al.Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection[J].J Clin Oncol, 2010, 28 (14) :2437-2444.

[36]KIM WR, LOOMBA R, BERG T, et al.Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B[J].Cancer, 2015, 121 (20) :3631-3638.

[37]PAPATHEODORIDIS G, DALEKOS G, SYPSA V, et al.PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy[J].J Hepatol, 2016, 64 (4) :800-806.

[38]HUNG YC, LIIN CL, LIU CJ, et al.Development of risk scoring system for stratifying population for hepatocellular carcinoma screening[J].Hepatology, 2015, 61 (6) :1934-1944.

[39]FLEMMING JA, YANG JD, VITTINGHOFF E, et al.Risk prediction of hepatocellular carcinoma in patients with circhosis:The ADRESS-HCC risk model[J].Cancer, 2014, 120 (22) :3485-3493.

[40]WATANABE M, YOMOKORI H, TAKAHASHI Y, et al.Regular hospital visits improve the prognosis of hepatocellular carcinoma after initial diagnosis:A single regional community hospital study[J].Turk J Gastroenterol, 2017, 28 (5) :353-360.

[41]ATIQ O, TIRO J, YOPP AC, et al.An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis[J].Hepatology, 2017, 65 (4) :1196-1205.

[42]LI P, DING HG, XU H, et al.Shortening liver cancer screening interval may improve the prognosis of patients with hepatitis B cirrhosis-related hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (7) :1301-1304. (in Chinese) 李鹏, 丁惠国, 徐辉, 等.缩短肝癌筛查间隔对乙型肝炎肝硬化相关肝细胞癌患者预后的影响[J].临床肝胆病杂志, 2017, 33 (7) :1301-1304.

施引文献

资源附件(0)

访问统计